Post-transplant lymphoproliferative disorder: risk factors and management
- 9 October 2019
- journal article
- editorial
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 36 (7), 1177-1179
- https://doi.org/10.1093/ndt/gfz207
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Variation in Cancer Incidence among Patients with ESRD during Kidney Function and Nonfunction IntervalsJournal of the American Society of Nephrology, 2015
- Lymphoproliferative Disorders After Adult Kidney Transplant: Epidemiology and Comparison of Registry Report With Claims-Based DiagnosesAmerican Journal of Kidney Diseases, 2011
- Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: a European Renal Best Practice (ERBP) position statementNephrology Dialysis Transplantation, 2011
- Management of post‐transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS GuidelinesBritish Journal of Haematology, 2010
- Epidemiology of Pretransplant EBV and CMV Serostatus in Relation to Posttransplant Non-Hodgkin LymphomaTransplantation, 2009
- Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantationBlood, 2009
- Ganciclovir and Acyclovir Reduce the Risk of Post‐Transplant Lymphoproliferative Disorder in Renal Transplant RecipientsAmerican Journal of Transplantation, 2005
- Cancer after Kidney Transplantation in the United StatesAmerican Journal of Transplantation, 2004
- Persistence of the Epstein–Barr Virus and the Origins of Associated LymphomasThe New England Journal of Medicine, 2004
- Pretransplantation Assessment of the Risk of Lymphoproliferative DisorderClinical Infectious Diseases, 1995